Fezolinetant for treating moderate to severe vasomotor symptoms associated with menopause (TA1143)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 31 March 2026
Menopause: identification and management (NG23)Product type:GuidanceProgramme:NICE guidelineLast updated: 7 November 2024Published: 12 November 2015
Removal, preservation and subsequent reimplantation of ovarian tissue to prevent symptoms from the menopause (HTG640)Product type:GuidanceProgramme:HealthTech guidancePublished: 21 September 2022
Transvaginal laser therapy for urogenital atrophy (HTG582)Product type:GuidanceProgramme:HealthTech guidancePublished: 26 May 2021
Estetrol for treating vasomotor symptoms associated with the menopause in people aged 40 to 65 [ID4037]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Women’s and reproductive health guidelinesStatus:In developmentProgramme:NICE HubExpected publication date: TBC
Elinzanetant for treating vasomotor symptoms associated with menopause [ID6359]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Elinzanetant for treating vasomotor symptoms caused by adjuvant endocrine treatment to prevent or treat hormone-receptor positive breast cancer [ID6544]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC